About 5'-AMP-activated protein kinase subunit beta-2
5'-AMP-activated protein kinase subunit beta-2 (PRKAB2) is a protein
from Homo sapiens identified by UniProt accession
O43741, 272 residues long.
MolForge cross-references it against 0 known binders and
160 disease associations.
Target properties
| Protein name | 5'-AMP-activated protein kinase subunit beta-2 |
|---|
| UniProt accession | O43741 |
|---|
| Gene | PRKAB2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 272 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (160)
Diseases linked to this target (Open Targets).
- granulocyte count · score 0.26
- neurodegenerative disease · score 0.26
- cardiovascular disease · score 0.26
- head and neck squamous cell carcinoma · score 0.24
- neuroinflammatory disorder · score 0.24
- squamous cell lung carcinoma · score 0.22
- adolescent idiopathic scoliosis · score 0.20
- body height · score 0.08
- blood protein measurement · score 0.08
- hyperinsulinism due to INSR deficiency · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O43741-F1 | alphafold | PREDICTED | 77.77 | — |
Amino-acid sequence (272 residues)
MGNTTSDRVS GERHGAKAAR SEGAGGHAPG KEHKIMVGST DDPSVFSLPD SKLPGDKEFV SWQQDLEDSV KPTQQARPTV IRWSEGGKEV FISGSFNNWS TKIPLIKSHN DFVAILDLPE GEHQYKFFVD GQWVHDPSEP VVTSQLGTIN NLIHVKKSDF EVFDALKLDS MESSETSCRD LSSSPPGPYG QEMYAFRSEE RFKSPPILPP HLLQVILNKD TNISCDPALL PEPNHVMLNH LYALSIKDSV MVLSATHRYK KKYVTTLLYK PI
Explore 5'-AMP-activated protein kinase subunit beta-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets